Practice patterns of sedation for colonoscopy - 13/08/15
Abstract |
Background |
Sedative and analgesic medications have been used routinely for decades to provide patient comfort, reduce procedure time, and improve examination quality during colonoscopy.
Objective |
To evaluate trends of sedation during colonoscopy in the United States.
Setting |
Endoscopic data repository of U.S. gastroenterology practices (Clinical Outcomes Research Initiative, CORI database from 2000 until 2013).
Patients |
The study population was made up of patients undergoing a total of 1,385,436 colonoscopies.
Interventions |
Colonoscopy without any intervention or with mucosal biopsy, polypectomy, various means of hemostasis, luminal dilation, stent placement, or ablation.
Main Outcome Measurements |
Dose of midazolam, diazepam, fentanyl, meperidine, diphenhydramine, promethazine, and propofol used for sedation during colonoscopy.
Results |
During the past 14 years, midazolam, fentanyl, and propofol have become the most commonly used sedatives for colonoscopy. Except for benzodiazepines, which were dosed higher in women than men, equal doses of sedation were given to female and male patients. White patients were given higher doses than other ethnic groups undergoing sedation for colonoscopy. Except for histamine-1 receptor antagonists, all sedative medications were given at lower doses to patients with increasing age. The dose of sedatives was higher in colonoscopies associated with procedural interventions or of long duration.
Limitations |
Potential for incomplete or incorrect documentation in the database.
Conclusion |
The findings reflect on colonoscopy practice in the United States during the last 14 years and provide an incentive for future research on how sex and ethnicity influence sedation practices.
Le texte complet de cet article est disponible en PDF.Abbreviations : ASGE, CORI
Plan
| DISCLOSURE: This project was supported with funding from NIDDK UO1 CA 89389-01, NIDDK U01 DK057132, and R33-DK61778-01. In addition, the practice network (Clinical Outcomes Research Initiative) has received support from the following entities to support the infrastructure of the practice-based network: AstraZeneca, Novartis, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon. All authors disclosed no financial relationships relevant to this article. |
Vol 82 - N° 3
P. 503-511 - septembre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
